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Abstract 
Background: In the present study, our objective was to evaluate and compare the clinical and microbiological 
results in patients receiving systemic and systemic plus inhaled colistin therapy due to nosocomial pneumonia (NP) or 
ventilator associated pneumonia (VAP) caused by Acinetobacter baumannii.
Methods: A retrospective matched case–control study was performed at the ICUs at Izmir Katip Celebi University 
Ataturk Training and Research Hospital from January 2013 to December 2014. Eighty patients who received only sys-
temic colistin were matched 43 patients who received systemic colistin combined with inhaled therapy.
Results: In 97.6 % of the patients colistin was co-administered with at least one additional antibiotic. The most 
frequently co-administered antibiotics were carbapenems (79.7 %). The patient groups did not differ significantly 
in terms of the non-colistin antibiotics used for treatment (p > 0.05). Acute renal injury was observed in 53.8 % and 
48.8 % of the patients who received parenteral colistin or parenteral plus inhaler colistin, respectively (p = 0.603). 
There were no significant differences between the groups in terms of clinical success (p = 0.974), clinical failure 
(p = 0.291), or recurrence (p = 0.094). Only, a significantly higher partial clinical improvement rate was observed in 
the systemic colistin group (p = 0.009). No significant differences between the two groups in terms of eradication 
(p = 0.712), persistence (p = 0.470), or recurrence (p = 0.356) rates was observed. One-month mortality rate was 
similar in systemic (47.5 %) and systemic plus inhaled (53.5 %) treatment groups (p = 0.526).
Conclusions: Our results suggest that combination of inhaled colistin with intravenous colistin had no additional 
therapeutic benefit in terms of clinical or microbiological outcomes.
© 2016 Demirdal et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Backgrounds
Nosocomial pneumonia and ventilator associated pneu-
monia (VAP) represent the most common form of 
healthcare associates infections (HAIs) [1]. Commonly 
gram negative bacteria with potential multiple drug 
resistance (MDR) such as Acinetobacter baumannii, 
Pseudomonas aeruginosa and Klebsiella pneumoniae are 
commonly associated with nosocomial pneumonia, par-
ticularly in intensive care units (ICU). The mortality rate 
of nosocomial pneumonia may reach up to 70  %, with 
even higher mortality rates when the causative agent has 
MDR [2]. Recent evidence is indicative of a continuous 
increase in the detection rate of antibiotic resistance in 
these microorganisms [3].
Colistin represents an important therapeutic option 
in infections caused by MDR gram negative bacteria, 
although there is a certain level of clinical reluctance to 
its use due to low penetration in the lung parenchyma as 
well as the efficacy of intravenous colistin in patients with 
suspected pneumonia [4]. Inhalational use of colistin pre-
vents systemic side effects, while providing high concen-
trations in the airways represents a significant advantage 
[5]. Studies have suggested that the lung concentrations 
of colistin obtained following the inhalational route of 
administration may reach levels adequate to eradicate the 
susceptible A. baumannii strains [6]. Currently, inhaled 
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colistin is widely and effectively used for the treatment of 
pulmonary exacerbations in cystic fibrosis patients colo-
nized by P. aeruginosa [7]. On the other hand, experience 
on the use of colistin in pneumonia caused by other MDR 
gram negative bacteria is limited. In the present study, 
our objective was to retrospectively evaluate and com-
pare the clinical and microbiological results in patients 
receiving systemic and systemic plus inhaled colistin 
therapy due to nosocomial pneumonia or (VAP) caused 
by A. baumannii.
Methods
Patients admitted to ICU for a minimum duration of 48 h 
between January 2013 and December 2014 were included 
in this retrospective study if they received systemic treat-
ment or systemic treatment in combination with inhaler 
colistin due to VAP or nosocomial pneumonia caused by 
A. baumannii. Patients whose length of ICU stays were 
shorter than 48 h were excluded as well as patients under 
18  years of age. In addition to demographic data, dura-
tion of treatment, concomitant antibiotics, presence of 
acute renal failure, and clinical and microbiological out-
comes were assessed. Systemic colistin dose was admin-
istered via intravenous route as 150  mg colistin base 
activity q12 h and inhaled colistin dose was administered 
via nebulizer 75  mg colistin base activity q12  h. Diag-
nosis of nephrotoxicity was based on RIFLE criteria [8]. 
A ≥1.5-fold increase in creatinine levels from baseline to 
treatment end was considered to represent acute renal 
injury. Strains isolated were identified using conventional 
methods. Definitive typing of the strains was performed 
using an automated BD Phoenix system (Becton Dickin-
son, USA) with antibiotic susceptibility testing. Results 
were analyzed using SPSS v22 software package.
For a diagnosis of pneumonia, at least two of the fol-
lowing supportive clinical signs were required in the 
presence of new or progressive pulmonary infiltrates in 
radiographic assessments: a body temperature >38  °C 
or <35.5  °C, leukocyte count >12,000  cells/mm3 or 
<4000  cells/mm3, purulent bronchial secretions, or 
reduced oxygenation [9]. Nosocomial pneumonia was 
defined as the one that was not in incubation period at 
admission and that developed >48  h after admission, 
while VAP was defined as the one that was not in the 
incubation period before the initiation of mechanical 
ventilation and that developed >48 h after intubation. A 
microbiological diagnosis was ascertained by growth of 
>104 CFU/ml in the bronchial or bronchoalveolar (BAL) 
fluid [10].
Clinical outcome was categorized as clinical success 
(resolution of the infection related signs and symptoms 
with colistin treatment), partial clinical improvement 
(partial improvement in the symptoms and signs of 
infection), clinical failure (persistence or worsening of the 
symptoms and signs of infection despite colistin admin-
istered at appropriate dose), recurrence (occurrence of a 
new infection episode at least 48 h after the initial clinical 
improvement with colistin). Microbiological results were 
categorized as eradication (eradication of the causative 
organism in samples after treatment), persistence (per-
sistence of the organism in clinical samples irrespective 
of the clinical status of the patient), recurrence (re-iden-
tification of the causative pathogen in clinical samples 
after initial eradication), colonization (persistence or re-
growth of the organism in clinical samples without any 
signs and symptoms of the infection). One-month mor-
tality was defined as death occurring within 30 days after 
the isolation of the causative organism.
Results
Of the 123 patients included, 40 (32.5 %) were female, and 
83 (67.5 %) were male, with a mean age of 64.15 ± 17.75 
(18–95) years. There were 83 cases (67.5  %) with VAP 
and 40 cases (32.5 %) with nosocomial pneumonia. The 
indications for intensive care admission included acute 
neurological disorder in 38.2  %, respiratory failure in 
26  % (n  =  32), post-operative resuscitation in 15.4  % 
(n = 19), trauma in 8.9 % (n = 11), septic shock in 5.7 % 
(n = 7), and cardiac arrest in 5.7 % (n = 7). Respiratory 
failure was significantly more common among those who 
received only systemic therapy (p = 0.025), while trauma 
was significantly more common in those who received 
systemic and inhaled therapy (p =  0.010). Other demo-
graphic characteristics were similar across the patients 
(Table  1). In 65  % of the cases (n  =  80) only systemic 
colistin was administered, while it was co-administered 
with inhaled therapy in 35 % (n =  43). In 97.6 % of the 
patients (n =  120) colistin was co-administered with at 
least one additional antibiotic. The most frequently co-
administered antibiotics were carbapenems (n  =  98, 
79.7  %), cefoperazone-sublactam (n  =  15, 12.2  %), fol-
lowed by tigecycline (n  =  7, 5.7  %), sulbactam (n  =  4, 
3.3  %), and ceftazidim (n  =  1, 0.8  %). Three patients 
(2.4 %) received carbapenem and tigecycline in conjunc-
tion with colistin, two patients (1.6 %) received carbape-
nem and cefoperazone-sulbactam with colistin, 1 patient 
(0.8 %) received tigecycline and sulbactam with colistin. 
The patient groups did not differ significantly in terms of 
the non-colistin antibiotics used for treatment (p > 0.05).
The average duration of intensive unit care was 
63.1 ± 51.67 days (11–287), and the average duration of 
colistin therapy was 11.2 ± 6.45 days (3–32).
The average baseline and end-of-treatment creatinine 
levels in patients who received only systemic or systemic 
plus inhaler colistin therapy were 0.82 ± 0.56/1.20 ± 0.89; 
1.65 ± 1.08/1.86 ± 1.22 mg/dl, respectively. In those who 
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received systemic therapy, the baseline creatinine levels 
were significantly lower as compared to the other group 
(p  =  0.009). Fifty-two percent (n  =  64) of the patients 
developed acute renal injury. Treatment was discontin-
ued in 22 patients (22  %) due to nephrotoxicity, and 5 
patients (4.1 %) required dialysis. Acute renal injury was 
observed in 53.8 % (n = 43) and 48.8 % (n = 21) of the 
patients who received parenteral colistin or parenteral 
plus inhaler colistin, respectively, with no significant dif-
ference between the groups (p  =  0.603). In addition to 
colistin, use of other nephrotoxic agents such as amino-
glycosides or glycopeptides was also examined. Of the 
study subjects, 53.7 % (n = 66) had a history of the use 
of another nephrotoxic agents. While 54.5 % (n = 36) of 
those who received another nephrotoxic agent developed 
acute renal injury, this figure was 49.1 % (n = 28) in those 
with no use of these agents, and the difference was not 
significant between the two groups (p = 0.548).
Table  2 shows the clinical and microbiological out-
comes as well as the one-month mortality rates in the 
treatment groups. Clinical success, partial improve-
ment, clinical failure and recurrence were observed in 
37.4 % (n = 46), 13 % (n = 57), 44.7 % (n = 55), and 4.9 % 
(n =  55), respectively. Clinical success was observed in 
37.5 % (n = 30) of the patients who received parenteral 
colistin only, while this figure was 37.2 % (n = 16) among 
those who received parenteral plus inhaler colistin, with 
no significant differences between the groups in terms of 
clinical success (p = 0.974), clinical failure (p = 0.291), or 
recurrence (p =  0.094). Only, a significantly higher par-
tial clinical improvement rate was observed in the sys-
temic colistin group (p = 0.009).
After the completion of colistin therapy, eradication, 
persistence, recurrence, or colonization were determined 
microbiologically in 48.8  % (n  =  60), 39.8  % (n  =  49), 
6.5 % (n = 8), and 4.9 % (n = 6) of the patients, respec-
tively. In those who received only parenteral colistin, 
the rate of microbiologic eradication was 50 % (n = 40), 
while this figure was 46.5  % in those who received par-
enteral and inhaled colistin (n  =  20). No significant 
differences between the two groups in terms of eradica-
tion (p =  0.712), persistence (p =  0.470), or recurrence 
Table 1 Demographics of  the patients received systemic, 
inhaler and systemic colistin therapy






n (%) n (%)
Age ± SD 62.80 ± 18.80 66.67 ± 15.49 0.290
Gender (M/F) 50/30 33/10 0.109
Cause of admission 0.386
 Respiratory failure 26 (32.5) 6 (14) 0.025
 Septic shock 3 (3.8) 4 (9.3) 0.205
 Trauma 7 (8.8) 4 (9.3) 0.010
 Post-op resuscitation 10 (12.5) 9 (20.9) 0.217
 Acute neurological disorder 29 (36.3) 18 (41.9) 0.541
 Cardiac arrest 5 (6.3) 2 (4.7) 0.715
Duration of ICU stay ± SD 57.68 ± 56.99 47.91 ± 47.02 0.514
Duration of colistin therapy ± SD 11.21 ± 6.714 11.23 ± 6.023 0.708
Infection
 HKP 25 (31.3) 15 (34.9) 0.681
 VIP 55 (68.7) 28 (65.1) 0.681
 Creatinine at baseline ± SD 0.82 ± 0.56 1.20 ± 0.89 0.009
 Creatinine at end-of-treat-
ment ± SD
1.65 ± 1.08 1.86 ± 1.22 0.469
 Nephrotoxic drug use 43 (53.8) 23 (53.5) 0.978
Underlying disorders
 Cerebrovascular event 17 (21.3) 11 (25.6) 0.584
 COPD 6 (7.5) 3 (7) 0.915
 CAD 28 (35) 22 (51.2) 0.081
 Diabetes mellitus 19 (23.8) 10 (23.3) 0.950
 CRF 5 (6.3) 3 (7) 0.876
Concomitant antibiotics
 Carbapenem 62 (77.5) 36 (83.7) 0.413
 Cefoperazon 
sulbactam
9 (11.3) 6 (14) 0.662
 Tigecycline 5 (6.3) 2 (4.7) 0.715
 Sulbactam 2 (2.5) 2 (4.7) 0.521
 Ceftazidime 1 (1.3) 0 (0) 0.461
Table 2 Clinical and microbiological outcome and mortal-
ity in  patients receiving systemic or systemic + inhaled 
colistin therapy
PE parenteral; Inh inhaled
PE colistin PE and inh.  
colistin
p
n (%) n (%)
Clinical outcome
 Clinical success 30 (37.5) 16 (37.2) 0.974
 Partial clinical  
improvement
15 (18.8) 1 (2.3) 0.009
 Clinical failure 33 (41.3) 22 (51.2) 0.291
 Recurrence 2 (2.5) 4 (9.3) 0.094
Microbiological outcome
 Eradication 40 (50) 20 (46.5) 0.712
 Persistence 30 (37.5) 19 (44.2) 0.470
 Recurrence 4 (5) 4 (9.3) 0.356
 Colonization 6 (7.5) 0 (0) 0.062
 Mortality 38 (47.5) 23 (53.5) 0.526
Side effects
 Nephrotoxicity 43 (53.8) 21 (48.8) 0.603
 Neurotoxicty 0 0
 Local side effects 0 0
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(p = 0.356) rates. There were no cases of colonization in 
the group that received inhaled colistin, while the differ-
ence with the group that received systemic therapy only 
was insignificant (p = 0.062).
One-month mortality rate after colistin therapy was 
49.6  % (n =  61). This figure in those who received par-
enteral colistin or parenteral plus inhaled colistin was 
47.5 % (n = 38) and 53.5 % (n = 23), with no significant 
difference (p = 0.526).
Discussion
Despite excellent bactericidal activity of colistin against 
majority of gram-negative organisms, it’s ineffective 
against gram-positive bacteria and anaerobes other than 
Prevotella spp., and Fusobacterium spp. [11]. Although 
it has a wide-spectrum of activity, its use has been lim-
ited to problematic organisms such as P. aeruginosa and 
A. baumannii due to its side effects [4]. In the collabo-
rative guidelines issued by the American Thoracic Soci-
ety (ATS) and Infectious Diseases Society of America 
(IDSA), it is recommended as a last resort for the treat-
ment of infections caused by MDR-negative gram nega-
tive organisms, and particularly for VAP developing in 
critically ill patients [10].
Ventilator associated pneumonia (VAP) is one of the 
most common types of HAIs, representing approximately 
15 % of all HAIs [12] and being associated with the high-
est morbidity and mortality rates among infections in 
the intensive care unit. It accounts for nearly 50 % of the 
total antibiotic use in the ICU. The incidence of hard-to-
treat organisms such as A. baumannii, P. aeruginosa, and 
carbapenem-resistant Enterobacteriaceae spp. is continu-
ously increasing, with resistance reported against all anti-
biotics including colistin in some centers [13].
MDR gram negative bacterial infections are increas-
ingly more frequently observed in intensive care units. 
Considering the limited therapeutic options and high 
mortality of these infections, the benefits that could be 
obtained through inhaled colistin use may be important. 
Theoretically, inhaled route of administration may allow 
direct access of the colistin to the site of infection and 
may allow prevention of renal or neurological side effects 
that may occur during systemic use [14]. Inhaled colistin 
is generally well tolerated, with rare cases of bronchoc-
onstriction [15], and no increase in the incidence of seri-
ous systemic side effects such as nephrotoxicity have 
been reported with inhaled colistin therapy [14, 16–19]. 
Similarly, inhaled colistin was well tolerated in our study, 
with no systemic or local side effects after its use. These 
results suggest that inhaled colistin therapy may be a safe 
therapeutic option in terms of side effects.
Many studies have reported on the efficacy of colistin, 
an important therapeutic option, on MDR gram-negative 
bacteria [20]. However, one of the most common side 
effects of colistin therapy is nephrotoxicity, which is par-
ticularly more common in patients with high baseline 
creatinine at the initiation of treatment. On the other 
hand, the reported frequency and severity of nephro-
toxicity is lower as compared to the figures reported in 
1970s [21]. Tumbarello et al. [22]. reported that 22 % of 
the patients had nephrotoxicity during inhaled therapy, 
while this figure was 25 % in inhaled plus systemic ther-
apy, with no significant differences (p = 0.62). Also, these 
authors suggested that the development of nephrotoxic-
ity was a risk factor for treatment failure. Kalin et al. [23] 
showed an increased incidence of nephrotoxicity with 
high dose systemic colistin as compared to normal or 
lower doses in VAP patients, while the differences were 
again insignificant. Nephrotoxicity occurred at a higher 
frequency among patients receiving inhaled colistin, with 
no significant difference with other groups. The incidence 
of nephrotoxicity reported by Kofteridis et  al. [14] and 
Rattanaumpawan et al. [17] were 19 % and 25.5 %, respec-
tively. In our study, acute renal injury was assessed using 
the RIFLE criteria and 64 patients (52 %) were found to 
have acute renal injury. In 27 patients (22 %) nephrotox-
icity resulted in the discontinuation of the treatment, 
and 5 patients (4.1 %) required hemodialysis. There were 
no significant differences in acute renal injury between 
patients who received systemic colistin and those who 
received combination of systemic and inhaled colis-
tin (p = 0.603). A comparison between patients with or 
without a history of the use of another nephrotoxic agent 
revealed no difference in the risk of developing acute 
renal injury (p = 0.548), suggesting that the nephrotoxic 
effects observed are most likely due to colistin. However, 
the observed rate of nephrotoxicity in our study is higher 
than those reported previously, which might have been 
due to the differences between studies with respect to the 
definition used for nephrotoxicity.
Despite a number of observational studies on the 
effect of inhaled colistin on clinical outcomes, prospec-
tive case–control studies examining patients who did or 
did not receive inhaled colistin are non-existent [24]. The 
benefits of inhaled colistin have been subject to contro-
versy, with some studies reporting beneficial effects, and 
others proposing no such benefits [14, 16, 25]. Kofteridis 
et al. [14] found no additional therapeutic benefits from 
adding inhaled colistin to systemic colistin in VAP caused 
by MDR gram-negative bacteria. Tumbarello et  al. [22] 
observed significantly higher rates of clinical improve-
ment in VAP caused by A. baumannii, P. aeruginosa, or 
K. pneumonia with inhaled colistin therapy. In another 
study examining patients with VAP caused by MDR 
A. baumannii strains, lower rates of clinical response 
was found among patients receiving inhaled therapy as 
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compared to patients who received intravenous therapy 
only, although the difference was not statistically signifi-
cant [23].
In a 2015 meta-analysis of inhaled colistin therapy in 
VAP patients, significant improvements in clinical out-
come, microbiological eradication, and infection-related 
mortality rates were found when inhaled colistin was 
added to systemic colistin [26]. Our results did not show 
any difference between parenteral plus inhaled colis-
tin therapy and parenteral colistin alone with regard to 
complete clinical response (p =  0.974). This result may 
be related with the fact that the clinical severity of the 
patients was not assessed in our study.
Microbiological cure could be achieved in 48.8  % of 
the patients who received systemic and inhaled colistin, 
with no differences between systemic colistin alone and 
combined inhaled and systemic colistin in this respect 
(p =  0.712). Hsieh et  al. [27] reported a microbiological 
success rate of 75  % among patients colonized with A. 
baumannii or diagnosed with pneumonia, while the fig-
ure found by Kofteridis et  al. [14] in patients with VAP 
was 45 %. In patients with VAP due to A. baumannii, the 
bacterial eradication rates with intravenous colistin treat-
ment and inhaled plus systemic colistin treatment were 
69 % and 76 %, respectively [23]. In the study by Rattan-
aumpawan et al. [17] addition of inhaled colistin to intra-
venous colistin a significant increase in microbiological 
cure rate was found (p =  0.03). Similarly Kuo et  al. [19] 
found a positive effect of inhaled colistin in terms of 
microbiological success, and identified inhaled colistin as 
an independent predictor for eradication. On the other 
hand, Tumbarello et al. [22], in their study involving VAP 
patients, claimed that use of inhaled colistin had no mean-
ingful effect on microbiological eradication. Similarly, our 
results showed no additional benefit from inhaled colistin. 
Use of inhaled colistin was associated with the absence of 
colonization, although the difference was not significant 
(p = 0.062). In several previous studies, the inoculum bur-
den of a specific micro-organism was shown to represent 
an important determinant of eradication [28]. The fact 
that the inoculum burden was not assessed in our study 
may have had an effect on our results.
Microorganisms associated with highest mortality in 
VAP patients include A. baumannii, P. aeruginosa, and 
methicillin-resistant S. aureus [10], placing an extra sig-
nificance on the investigation of an additional therapeu-
tic benefit of inhaled colistin in these patients.
In our study, the one-month mortality was 61.4 %, with 
no significant difference between inhaled colistin alone 
and inhaled plus systemic colistin in terms of mortality 
(p = 0.942). In the study by Korbila et al. [18] involving 
VAP patients, mortality rate with inhaled colistin and 
combined systemic and inhaled colistin groups were 
39.7 and 44.2  %, respectively. Again the overall mortal-
ity in VAP caused by MDR gram negative organisms in 
the study by Michalopoulos et  al. [16] was 25  %, while 
the VAP-associated mortality was 16.7 %, among patients 
receiving inhaled colistin. In previous studies, mortal-
ity rates were comparable between inhaled colistin and 
intravenous plus inhaled colistin, with no significant 
differences [14, 18, 22, 29]. In line with these previous 
reports, we did not find any significant effect of inhaled 
treatment on mortality (p = 0.526).
In nosocomial pneumonia due to multi-drug resist-
ant gram-negative bacteria, inhaled colistin therapy rep-
resents a promising approach owing to the side effects 
systemic colistin treatment. Our results suggest that 
combination of inhaled colistin with intravenous colis-
tin and/or non-colistin antibiotics had no additional 
therapeutic benefit in terms of clinical or microbiologi-
cal outcomes, with no additional mortality benefit. How-
ever due to the presence of certain limitations such as 
the retrospective nature of our study and absence of the 
assessment of the disease severity, further prospective-
controlled studies are warranted to minimize the effect of 
such confounding factors.
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